Antibody targeting of HER2/HER3 signaling overcomes heregulin‐induced resistance to PI3K inhibition in prostate cancer

E-ISSN： 1097-0215|137|2|267-277

ISSN： 0020-7136

Source： INTERNATIONAL JOURNAL OF CANCER, Vol.137, Iss.2, 2015-07, pp. : 267-277

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma

CANCER, Vol. 121, Iss. 20, 2015-10 ,pp. : 3600-3611

John Wiley & Sons Inc

Access to resources Recommend Favorite

Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration‐resistant prostate cancer

THE PROSTATE, Vol. 270-4137, Iss. 15, 2015-11 ,pp. : 1747-1759

John Wiley & Sons Inc

Access to resources Recommend Favorite

Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration‐resistant prostate cancer

THE PROSTATE, Vol. 75, Iss. 15, 2015-11 ,pp. : 1747-1759

John Wiley & Sons Inc

Access to resources Recommend Favorite

The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis

By Wang Yaohui Liu Yu Du Yueyao Yin Wenjin Lu Jinsong

Current Medical Research and Opinion, Vol. 29, Iss. 6, 2013-06 ,pp. : 633-642

Informa Healthcare

Access to resources Recommend Favorite

GOLM1 promotes prostate cancer progression through activating PI3K‐AKT‐mTOR signaling

THE PROSTATE, Vol. 78, Iss. 3, 2018-02 ,pp. : 166-177

John Wiley & Sons Inc

Access to resources Recommend Favorite